Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Executive VP & CMO | June 15, 2017 | June 16, 2017 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | CHIEF MEDICAL OFFICER | April 04, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 15, 2017 · Filed June 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2027-06-15 | Direct | 150,000 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
F2: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
GENOCEA BIOSCIENCES, INC.
Report date April 04, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,330 |
Reported balance
After 2022-04-04 transaction · row 1
1 source rowRow 1 · 2022-04-04 · Sale · Disposed 1,091 · Balance 68,330 F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 5, 2022 08:17 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 1,091 | $1.25 | $1,363.75 |
DisclosureSEC source: 0001457612-22-000044 · wf-form4_164916101204761.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,330 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 16:09 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 2,717 | $1.10 | $2,988.70 |
DisclosureSEC source: 0001457612-22-000028 · wf-form4_164754772688295.xml · nonDerivative · entry 2 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,421 F2 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:09 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 93,750 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001457612-22-000028 · wf-form4_164754772688295.xml · derivative · entry 3 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2032-03-15 F3 · derivative.exercise_date: The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:09 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-22-000028 · wf-form4_164754772688295.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,138 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| June 01, 2021 Filed Mar 16, 2022 17:29 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 524 | $2.23 | $1,168.52 |
DisclosureSEC source: 0001457612-22-000018 · wf-form5_164746616934998.xml · nonDerivative · entry 2 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,700 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 02, 2021 Filed Mar 16, 2022 17:29 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 948 | $2.71 | $2,569.08 |
DisclosureSEC source: 0001457612-22-000018 · wf-form5_164746616934998.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,224 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:50 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000034 · wf-form4_161600344570799.xml · derivative · entry 3 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. F4 · derivative.expiration_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:50 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 93,750 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001457612-21-000034 · wf-form4_161600344570799.xml · derivative · entry 2 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2031-03-15 F2 · derivative.exercise_date: The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:50 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000034 · wf-form4_161600344570799.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:24 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 24,938 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001457612-20-000082 · wf-form4_159112944346474.xml · derivative · entry 2 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,938 Underlying: Common Stock · 24,938 shares Expires 2030-06-01 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:24 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 6,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000082 · wf-form4_159112944346474.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:18 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 46,313 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001457612-20-000031 · wf-form4_158620430362691.xml · derivative · entry 2 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,313 Underlying: Common Stock · 46,313 shares Expires 2030-04-02 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:18 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 12,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000031 · wf-form4_158620430362691.xml · nonDerivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,299 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:00 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001457612-19-000016 · wf-form4_154993679883544.xml · derivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest). Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:25 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001457612-18-000101 · wf-form4_153852273097686.xml · derivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-01 F1 · derivative.exercise_date: 1. The Stock Option shall become exercisable as to 25% of the maximum number of shares on October 1, 2019, and as to an additional 2.0833% of the total number of shares on each monthly anniversary thereafter Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:27 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009155 · edgar.xml · derivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · Executive VP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.